VistaGen Therapeutics (NASDAQ:VTGN) just reported results for the first quarter of 2025.
- VistaGen Therapeutics reported earnings per share of -35 cents. This was above the analyst estimate for EPS of -40 cents.
- The company reported revenue of $84,000.
- This was 72% worse than the analyst estimate for revenue of $300,000.